Rapid antibody response after vaccination with a virosomal hepatitis A vaccine

Infection

Volumn 32, Issue 3, 2004, Pages 149-152

  Ambrosch, F ^a   Finkel, B ^b   Herzog, C ^b   Koren, A ^a   Kollaritsch, H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ADULT; ANTIBODY PRODUCING CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A VIRUS; HUMAN; MALE; MEASUREMENT; NORMAL HUMAN; PROTECTION; VACCINATION; VIRUS INFECTION;

ADOLESCENT; ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TIME FACTORS; VACCINATION; VACCINES, VIROSOME;

EID: 2942531147     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3147-4     Document Type: Article

References (18)

1. Koff RS: Hepatitis A. Lancet 1998; 351: 1643-1649.
2. Cuthbert JA: Hepatitis A: old and new. Clin Microbiol Rev 2001; 14: 38-58.
3. World Health Organization: Hepatitis A vaccines. WHO position paper. Wkly Epidemiol Rec 2000; 5: 38-44.
4. Just M, Berger R, Drechsler H, Brantschen S, Glück R: A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine 1992; 10: 737-739.
5. Loutan L, Bovier P, Althaus B, Glück R: Inactivated virosome hepatitis A vaccine. Lancet 1994; 343: 322-324.
6. Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Glück R, Herzog C: Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15: 1209-1213.
7. Holzer BR, Hatz C, Schmidt-Sissolak D, Glück R, Althaus B, Egger M: Immunogenicity and adverse effects of inactivated virosome versus alum-absorbed hepatitis A: a randomized controlled trial. Vaccine 1996; 14: 982-986.
8. Bovier PA, Althaus B, Glueck R, Chippaux A, Loutan L: Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med 1999; 6: 228-233.
9. Perez OM, Herzog C, Zellmeyer M, Loaisiga A, Frösner G, Egger M: Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis 2003; 188: 671-677.
10. Centers for Disease Control and Prevention: Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999; 48: 1-38.
11. Frösner G: Hepatitis A virus: Belshe, R. B.: Textbook of human virology 2002. Mosby Year Book, Inc., St. Louis 2002, pp 498-516.
12. Iwarson S: Immunisation against hepatitis A- active or passive. Infection 1996; 24: 2-4.
13. Flehmig B, Staedele H, Xueref C, Vidor E, Zuckerman J, Zuckerman A: Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine. J Infect 1997; 35: 37-40.
14. Maiwald H, Jilg W, Bock HL, Loscher T, Sonnenburg FV: Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 1997; 15: 346-348.
15. Landry P, Tremblay S, Darioli R, Genton B: Inactivated hepatitis A vaccine booster given >24 months after the primary dose. Vaccine 2001; 19: 399-402.
16. Lemon SM, Binn LN: Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983; 148: 1033-1039.
17. VanDamme P, Mathei C, Thoelen S, Meheus A, Safary A, André FE: Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994; 44: 435-441.
18. Bovier PA, Loutan L, Farinelli T, Bock J, Glueck R, Herzog C: Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 2002; 68: 489-493.